Alzheimer ’s ‘breakthrough’ stalls: why a much-hyped drug is facing approval delays

The benefits of drugs such as donanemab, aducanumab and lecanemab are proving harder to quantify than potential harms, experts sayIt was heralded in news articles as a “breakthrough”, a “turning point” and a “gamechanger” for Alzheimer’s disease. Some experts went so far as to call the drug, donanemab, the “beginning of the end” for the debilitating condition.Pharmaceutical company Eli Lillyin May 2023 released data from a clinical trial they said showed donanemab slowed cognitive and functional decline in people with early symptomatic Alzheimer ’s disease by 35% over 18 months.Continue reading...
Source: Guardian Unlimited Science - Category: Science Authors: Tags: Dementia Alzheimer's Health Medical research Australia news Source Type: news